Apolipoprotein E (ApoE) and Metabolism
Completed
Conditions studied: Cognitive Function, Healthy
In brief
Impaired metabolism and the gene apolipoprotein E (ApoE) are independent risk factors for cognitive impairment and dementia. In humans, there are three major versions of apoE (E): E2, E3, and E4. Some studies suggest that the different versions of apoE have varying effects on whole body and brain metabolism. The goal of this project is to better understand the relationship between apoE and metabolism. This will help investigators identify new targets for the prevention and treatment of cognitive decline and dementia.
Key facts
- Study ID
- NCT03109561
- Run by
- Lance Johnson
- People needed
- 100
- Starts
- 2018-04-24
- Expected to finish
- 2020-01-30
- Last updated by the study team
- 2020-07-23
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- all races/ethnicities
- ages 18-65
- cognitively normal
- good health
You may not qualify if…
- pregnant or breastfeeding.
- have a bleeding disorder,
- have a history of stroke, seizures, Parkinson's disease, history of head injury with loss of consciousness, or other dementing disorder.
- have a history of alcoholism or drug abuse
- have a history of schizophrenia or currently suffer from bipolar disorder or major depression.
- have vision or hearing loss severe enough to interfere with cognitive testing
Where it is running
- University of Kentucky Medical Center — Lexington, Kentucky, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.